stoxline Quote Chart Rank Option Currency Glossary
  
Editas Medicine, Inc. (EDIT)
5.61  -0.24 (-4.1%)    04-17 16:00
Open: 5.89
High: 5.9
Volume: 1,905,196
  
Pre. Close: 5.85
Low: 5.6
Market Cap: 459(M)
Technical analysis
2024-04-17 4:46:17 PM
Short term     
Mid term     
Targets 6-month :  8.89 1-year :  10.34
Resists First :  7.61 Second :  8.85
Pivot price 6.67
Supports First :  5.59 Second :  4.65
MAs MA(5) :  6.06 MA(20) :  6.89
MA(100) :  8.67 MA(250) :  8.55
MACD MACD :  -0.6 Signal :  -0.5
%K %D K(14,3) :  2.3 D(3) :  4
RSI RSI(14): 24.4
52-week High :  11.9 Low :  5.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EDIT ] has closed below the lower bollinger band by 0.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.94 - 6 6 - 6.03
Low: 5.48 - 5.55 5.55 - 5.6
Close: 5.53 - 5.64 5.64 - 5.72
Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Headline News

Mon, 15 Apr 2024
Editas Medicine (NASDAQ:EDIT) Hits New 52-Week Low at $6.05 - MarketBeat

Sun, 14 Apr 2024
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal - Yahoo Movies UK

Sun, 14 Apr 2024
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat

Sat, 06 Apr 2024
Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week - Simply Wall St

Tue, 12 Mar 2024
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) - Seeking Alpha

Sat, 09 Mar 2024
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 82 (M)
Shares Float 76 (M)
Held by Insiders 0.9 (%)
Held by Institutions 80.4 (%)
Shares Short 16,360 (K)
Shares Short P.Month 13,520 (K)
Stock Financials
EPS -2.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.26
Profit Margin -196.2 %
Operating Margin -40 %
Return on Assets (ttm) -20.9 %
Return on Equity (ttm) -43.2 %
Qtrly Rev. Growth 818.7 %
Gross Profit (p.s.) 0
Sales Per Share 0.95
EBITDA (p.s.) -2
Qtrly Earnings Growth 0 %
Operating Cash Flow -132 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -2.78
PEG Ratio -1.5
Price to Book value 1.31
Price to Sales 5.87
Price to Cash Flow -3.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android